Pancreatic cancer remains one of the most challenging cancers to detect and treat, with significant disparities affecting certain populations. The Hirshberg Foundation is dedicated to improving outcomes through research, awareness, and support, particularly focusing on family genetics, early detection and high-risk communities.
While most pancreatic cancers develop due to acquired gene mutations influenced by factors like smoking, obesity, age, and chronic pancreatitis, genetic predispositions can play a significant role. Approximately 10% of pancreatic cancer cases are hereditary, linked to inherited gene mutations known as Familial Pancreatic Cancer (FPC). FPC refers to families with at least two immediate family members with pancreatic cancer but no known hereditary cancer syndrome.
If you have a first-degree relative diagnosed with pancreatic cancer, your risk of developing the disease may be increased. It is strongly advised that your family member undergo genetic testing for inherited mutations. If their test results are negative, you typically may not need genetic testing. However, if their results are positive or uncertain, or if multiple close relatives have cancer, it is recommended to consult with a genetic counselor to determine if you should undergo genetic testing for inherited cancer risks and consider monitoring options. The risk increases further if more family members are affected or if there is a history of certain familial cancers. About 10% of pancreatic cancer cases are due to inherited mutations.
Black Americans are disproportionately affected by pancreatic cancer, facing higher incidence rates and significant obstacles to early detection and treatment, exacerbated by socioeconomic disparities, racial discrimination in healthcare settings, and late-stage diagnoses. Additionally, Ashkenazi Jews also face a higher incidence, possibly due to mutations in the BRCA1 or BRCA2 genes, which are associated with hereditary cancer predisposition.
To help further understand these risk factors and monitor individuals with genetic risks, researchers have established pancreatic cancer tumor registries. These registries include:
- The Pancreatic Tumor Registry at Memorial Sloan Kettering Cancer Center (MSKCC)
- The National Familial Pancreatic Tumor Registry (NFPTR) at Johns Hopkins University
- The Cancer of the Pancreas Screening-5 (CAPS5) Study which is also a clinical trial currently conducted at 8 universities
- The Pancreatic Cancer Early Detection (PRECEDE) Consortium an international, multi-institutional long-term study of individuals with an increased risk for pancreatic cancer
These pancreatic cancer tumor registries collect valuable data that can lead to early detection and potentially life-saving interventions for high-risk individuals.
Addressing pancreatic cancer requires a multifaceted approach that includes understanding genetic risks, improving early detection, and ensuring equitable healthcare. The Hirshberg Foundation is committed to transforming outcomes for high-risk families and communities through research, education, and support.
Resources:
- Hirshberg Foundation – Paving the Way to Better Outcomes
- American Cancer Society – Health Disparities Research
- FDA – Racial and Ethnic Minorities in Clinical Trials
- National Institutes of Health – Clinical Trial List
Through research, education, and community support, we strive to make significant strides in the fight against pancreatic cancer, ensuring no one faces this disease alone.